Haematopoietic stem and progenitor cells: Enumeration, phenotypic characterisation, and clinical applications

Transfusion Medicine and Hemotherapy

Volumn 31, Issue 5, 2004, Pages 341-352

  Levering, W H B M ^a,e   Sutherland, D R ^b   Keeney, M ^c   Kraan, J ^d   Gratama, J W ^d  

^a Lab Histocompatibility/Immunogen   (Netherlands)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Lab Histocompatibility Immunogen   (Netherlands)

Author keywords

CD34 enumeration; Flow cytometry; Haematopoietic stem cells; Single platform technique

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APHERESIS; BLOOD; BLOOD TRANSFUSION; BONE MARROW; CELL COUNT; CELL SUBPOPULATION; CELL VIABILITY; CYTOMETRY; FLOW CYTOMETRY; GENE THERAPY; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL; HUMAN; PHENOTYPE; REVIEW; STEM CELL; T LYMPHOCYTE; TUMOR CELL; UMBILICAL CORD;

EID: 5644300860     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081193     Document Type: Review

References (103)

1. Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW: Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Eng J Med 1957;257:491-496.
2. Buckner CD: Autologous bone marrow transplants to hematopoietic stem cell support with peripheral blood stem cells: A historical perspective. J Hematother 1999;8:233-236.
3. To LB, Haylock DN, Simmons PJ, Juttner CA: The biology and clinical uses of blood stem cells. Blood 1997;89;2233-2258.
4. Gluckman E: Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol 2000;28:1197-1205.
5. Berenson RJ, Andrews RG, Bensinger WI, Kalamasz D, Knitter G, Buckner CD, Bernstein ID: Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 1988;81:951-955.
6. Berenson RJ, Bensinger WI, Hill RS, Andrews RG, Garcia-Lopez J, Kalamasz DF, Still BJ, Spitzer G, Buckner D, Bernstein ID, Thomas ED: Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991;77:1717-1722.
7. Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, DiPersio J, Anderson K, Berenson J: Multicenter phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999;93:1858-1868.
8. Chapple P, Prince HM, Quinn M, Bertoncello I, Juneja S, Wolf M, Januszewicz H, Brettell M, Gardyn J, Seymour C, Venter D: Peripheral blood CD34+ cell count reliably predicts autograft yield. Bone Marrow Transplant 1998;22:125-130.
9. Weaver CH, Potz J, Redmond J, Tauer K, Schwartzberg LS, Kaywin P, Drapkin R, Grant B, Unger P, Allen, Longin K, Zhen B, Hazelton B, Buckner CD: Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cell with a low CD34+ cell content. Bone Marrow Transplant 1997;19:1103-1110.
10. Watts MJ: Clinical relevance of CD34+ cell measurements in PBSC transplantation. Cytotherapy 1999;1:348-350.
11. Siena S, Bregni M, Brando B, Belli N, Lansdorp PM, Bonadonna G, Gianni M: Flow cytometry to estimate circulating hematopoietic progenitors for autologous transplantation: Comparative analysis of different CD34 monoclonal antibodies. Haematologica 1991;76:330-333.
12. Siena S, Bregni M, Di Nicola M, et al: Milan protocol for clinical CD34+ cell estimation in peripheral blood for autografting in patients with cancer; in Wunder E, Sovalat H, Henon PR et al (eds): Hematopoietic Stem Cells: The Mulhouse Manual. Dayton, AlphaMed Press, 1994, pp 23-30.
13. Bender JG, Unverzagt K, Walker D: Guidelines for determination of CD34+ cells by flow cytometry: Application to the harvesting and transplantation of peripheral blood stem cells; in Wunder E, Sovalat H, Henon PR (eds): Hematopoietic Stem Cells. The Mulhouse Manual. Dayton, Alpha Med Press, 1994, pp 31-34.
14. Johnsen HE, Knudsen LM: Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: Report on the Second Nordic Workshop. J Hematother 1996;5:237-245.
15. Brecher ME, Sims L, Schmitz J, Shea T, Bentley SA: North American multicenter study on flow cytometric enumeration of CD34+ hematopoietic stem cells. J Hematother 1996;5:227-236.
16. Chang A, Ma DDF: The influence of flow cytometric gating strategy on the standardization of CD34+ cell quantitation: An Australian multicenter study. J Hematother 1996;5:605-616.
17. Rock G, Chin-Yee I, Cantin G, Giulivi A, Gluck S, Keating A, Keeney M, Klassen J, Sutherland R: Quality assurance of progenitor cell content of apheresis products: A comparison of clonogenic assays and CD34+ enumeration. Transfus Med 2000;10:67-75.
18. Sutherland DR, Keating A, Nayar R, Anania S, Stewart AK: Sensitive detection and enumeration of CD34+ cells in peripheral blood and cord blood by flow cytometry. Exp Hematol 1994;22:1003-1010.
19. Sutherland DR, Anderson L. Keeney M, Nayar R, Chin-Yee I: The ISHAGE guidelines for CD34+ cell enumeration by flow cytometry. J Hematother 1996;3:213-226.
20. Sutherland DR, Keeney M, Gratama JW: Enumeration of CD34+ hematopoietic stem and progenitor cells; in Current Protocols in Cytometry. New York, Wiley and Sons, 2003, pp 6.4.1-6.4.23.
21. Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR: Single-platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. Cytometry 1998;34:61-70.
22. Gratama JW, Orfoa A, Barnett D, Brando B, Huber A, Janossy G, Johnsen HE, Keeney M, Marti GE, Preijers F, Rothe G, Serke S, Sutherland DR, Van der Schoot E, Schmitz G, Papa S: Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells. Cytometry 1998;34:128-142.
23. Gratama JW, Keeney M, Sutherland DR: Enumeration of CD34+ hematopoietic stem and progenitor cells; in Current Protocols in Cytometry. New York, Wiley and Sons, 1999, pp 6.4.1-6.4.22.
24. Barnett D, Granger V, Kraan J, Whitby L, Reilly T, Papa S, Gratama JW: Reduction of intra- and inter-laboratory variation in CD34+ stem cell enumeration using stable test material, standard protocols and targeted training. Br J Haematol 2000;108:784-792.
25. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH: Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984;133;157-165.
26. Tindle RW, Nochols RA, Chan L, Campana D, Catovsky D, Birnie GD: A novel monoclonal antibody B1-3C5 recognises myeloblasts and non-B non-T lymphoblasts in acute leukaemias and CGL blast crises, and reacts with immature cells in normal bone marrow. Leuk Res 1985;9:1-9.
27. Katz F, Tindle R, Sutherland DR, Greaves MF: Identification of a membrane glycoprotein associated with haemopoietic progenitor cells. Leuk Res 1985;9:191-198.
28. Andrews RG, Singer JW, Bernstein ID: Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 1986;67:842-845.
29. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
30. Murray L, Chen B, Galy A, Chen S, Tushinski R, Uchida N, Negrin R, Tricot G, Jagannath S, Vesole D: Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood. Blood 1995;85:368-378.
31. Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR: Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood 1991;77:1218-1227.
32. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-5012.
33. Bender JG, Unverzagt KL, Walker DE, Lee W, Van Epps DE, Smith DH, Stewart CC, To LB: Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood 1991;77:2591-2596.
34. Sutherland DR, Yeo EL, Stewart AK, Nayar R, DiGiusto R, Zanjani E, Hoffman R, Murray LJ: Identification of CD34+ subsets after glycoprotease selection: Engraftment of CD34+Thy-1+Lin- stem cells in fetal sheep. Exp Hematol 1996;7:795-806.
35. Bhatia M: AC133 expression in human stem cells. Leukemia 2001;15:1685-1688.
36. Negrin RS, Atkinson K, Leemhuis T, Hanania E, Juttner C, Tierney K, Hu, WW, Johnston LJ, Shizuru JA, Stockerl-Goldstein KE, Blume KG, Weissman IL, Bower S, Baynes R, Dansey R, Karanes C, Peters W, Klein J: Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant 2000;6:262-271.
37. Vose JM, Bierman PJ, Lynch JC, Atkinson K, Juttner C, Hanania CE, Bociek G, Armitage JO: Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2001;7:680-687.
38. Michallet M, Philip T, Philip I, Godinot H, Sebban C, Salles G, Thiebaut A, Biron P, Lopez F, Mazars P, Roubi N, Leemhuis T, Hanania E, Reading C, Fine G, Atkinson K, Juttner C, Coiffier B, Fiere D, Archimbaud E: Transplantation with selected autologous peripheral blood CD34+Thy+ hematopoietic stem cells (HSCs) in multiple myeloma: Impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol 2000;28:858-870.
39. Sumikuma T, Shimazaki C, Inaba T, Ochiai N, Okano A, Hatsuse M, Ashihara E, Nakagawa M: CD34+/CD90+ cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation. Br J Haematol 2002;117:238-244.
40. Koehl U, Zimmermann S, Esser R, Sorensen J, Gruttner HP, Duchscherer M, Seifried E, Klingebiel T, Schwabe D: Autologous transplantation of CD133 selected hematopoietic progenitor cells in a pediatric patient with relapsed leukemia. Bone Marrow Transplant 2002;29:927-930.
41. To LB, Haylock DN, Simmons PJ, Juttner CA: The biology and clinical uses of blood stem cells. Blood 1997;89;2233-2258.
42. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W: An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995 85:3961-3969.
43. Gazitt Y, Liu Q: Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. Stem Cells 2001;19:37-45.
44. Stewart DA, Guo D, Luider J, Auer I, Klassen J, Ching E, Morris D, Chaudry A, Brown C, Russell JA: Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose. Bone Marrow Transplant 1999;23:1237-1243.
45. Sutherland DR, Keating A: The CD34 antigen: Structure, biology, and potential clinical applications. J Hematother 1992;1:115-129.
46. Lanza F, Healy L, Sutherland DR: Structural and functional features of the CD34 antigen: An update. J Biol Regul Homeost Agents 2001;15:1-13.
47. Barnett B, Janossy G, Lubenko A, Matutes E, Newland A, Reilly JT: Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Clin Lab Haematol 1999;21:301-308.
48. Gratama JW, Braakman E, Kraan J, Lankheet P, Levering WH, Van Den Beemd MW, Van Der Schoot CE, Wijermans P, Preijers F: Comparison of single and dual-platform assay formats for CD34+ haematopoietic progenitor cell enumeration. Clin Lab Haematol 1999;21:337-346.
49. Gutensohn K, Carrero I, Krueger W, Kroeger N, Schafer P, Luedemann K, Kuehnl P: Semi-automated flow cytometric analysis of CD34-expressing hematopoietic cells in peripheral blood progenitor cell apheresis products. Transfusion 1999;39:1220-1226.
50. Keeney M, Brown W, Gratama J, Papa S, Lanza F, Sutherland DR: Immunophenotypic characterization of CD34(pos) cells. J Biol Regul Homeost Agents 2003;17:254-260.
51. Stelzer GT, Shults KE, Loken MR: CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 1993;677:265-280.
52. Borowitz MJ, Günther KL, Shults KE, Stelzer GT: Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993;100:534-540.
53. Chin-Yee IH, Keeney M, Anderson L, Nayar R, Sutherland DR: Current status of CD34+ cell analysis by flow cytometry: The ISHAGE guidelines. Clin Immunol Newslett 1997;17:21-29.
54. Keeney M, Gratama JW, Chin-Yee IH, Sutherland DR: Isotype controls in the analysis of lymphocytes and CD34+ stem and progenitor cells by flow cytometry - time to let go! Cytometry 1998;34:280-283.
55. Brocklebank AM, Sparrow RL: Enumeration of CD34+ cells in cord blood: A variation on a single-platform flow cytometric method based on the ISHAGE gating strategy. Cytometry 2001;46:254-261.
56. Barnett D, Granger V, Whitby L, Storie I, Reilly T: Absolute CD4+ T-lymphocyte and CD34+ stem cell counts by single-platform flow cytometry: The way forward. Br J Haematol 1999;106:1059-1062.
57. Rosillo MC, Ortuno F, Rivera J, Moraleda JM, Vicente V: Cryopreservation modifies flow-cytometric analysis of hemopoietic cells. Vox Sang 1995;68:210-214.
58. Lanza F, Moretti S, Castagnari B, Montanelli F, Latorraca A, Ferrari L, Bardi A, Dominici M, Campioni D, Dabusti M, Piva N, Lodi G, Reverberi R, Castoldi G: Assessment of distribution of CD34 epitope classes in fresh and crypreserved peripheral blood progenitor cells and acute myeloid leukemic blasts. Haematologica 1999;84:969-977.
59. Schuurhuis GJ, Monnee-van Muijen M, Oberink JW, De Boer F, Ossenkoppele GJ, Broxterman HJ: Large populations of non-clonogenic early apoptotic CD34-positive cells are present in frozen-thawed peripheral blood stem cell transplants. Bone Marrow Transplant 2001;27:487-498.
60. De Boer F, Drager AM, Pinedo HM, Kessler FL, Monnee-van Muijen M, Weijers G, Westra G, Van der Wall E, Netelenbos T, Oberink JW, Huijgens PC, Schuurhuis GJ: Early apoptosis largely accounts for functional impairment of CD34+ cells in frozen-thawed stem cell grafts. J Hematother Stem Cell Res 2002;11:951-963.
61. De Boer F, Dräger AM, Pinedo HM, Kessler FL, Van der Wall E, Jonkhoff AR, Van der Lelie J, Huijgens PC, Ossenkoppele GJ, Schuurhuis GJ: Extensive early apoptosis in frozen-thawed CD34-positive stem cells decreases threshold doses for haematological recovery after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002;29:249-255.
62. Serke S, Van Lessen A, Pardo I, Huhn D: Selective susceptibility of CD34-expressing cells to acquire flow cytometric features of apoptosis/necrosis on exposure to an ammonium chloride-based red blood cell lysing reagent. J Hematother 1998;7:315-318.
63. Keeney M, Chin-Yee I, Nayar R, Sutherland DR: Effect of fixatives on CD34+ cell enumeration. J Hematother Stem Cell Res 1999;8:327-329.
64. Goldman JM, Horowitz MM: The international bone marrow transplant registry. Int J Hematol 2002;76:393-397.
65. Sampol A, Besalduch J, Galméz A, Bargay J, Matamoros N, Morey M, Novo A, Mascaro M, González E, Martínez P: CD34+ cell dose and CD33- subsets: Collection and engraftment kinetics in autologous peripheral blood stem cells transplantation. Haematologica 1998;83:489-495.
66. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH: Peripheral blood stem cells, number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:967-972.
67. Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF, Singhal S, Gordon LI, Mehta J: Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;31:861-864.
68. Schulman KA, Birch R, Zhen B, Pania N, Weaver CH: Effect on CD34+ cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol 1999;17:1227-1233.
69. Dercksen MW, Gerritsen WR, Rodenhuis S, Dirkson MK, Slaper-Cortenbach IC, Schaasberg WP, Pinedo HM, von dem Borne AE, van der Schoot CE: Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood 1995;85:3313-3319.
70. Pecora AL, Preti RA, Gleim GW, Jennis A, Zahos K, Cantwell S, Doria L, Isaacs R, Gillio AP, Michelis MA, Brochstein JA: CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. J Clin Oncol 1998;6:2093-2104.
71. Henon P, Sovalat H, Bourderont D, Ojeda-Uribe M, Arkam Y, Wunder E, Raidot JP, Husseini F, Audhuy B: Role of the CD34+ 38- cells in post transplant hematopoietic recovery. Stem Cells 1998;16:113-122.
72. Ringdén O, Barret J, Zhang MJ, Loberiza FR, Bolwell BJ, Cairo MS, Gale RP, Hale GA Litzow MR, Martino R, Russell JA, Tiberghien P, Urbano-Ispizua A, Horowitz MM: Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cells transplants with high CD34 cell doses. Br J Haematol 2003;121:874-885.
73. Heimfeld S: HLA-identical stem cell transplantation: Is there an optimal CD34 cell dose? Bone Marrow Transplant 2003;31:839-845.
74. Bittencourt H, Rocha V, Chevret S, Socié G, Espérou H, Devergie A, Dal Cortivo L, Marolleau JP, Garnier F, Ribaud P, Gluckman E: Association of CD34+ cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002;99:2726-2733.
75. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Körbling M, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Van Besien K, Andersson BS, Anderlini P, Champlin R: Risk factors for acute graft-versus-host-disease after allogeneic blood stem cell transplantation. Blood 1999;94:1465-1470.
76. Cornelissen JJ, Van der Holt B, Petersen EJ, Vindelov L, Russel CA, Höglund M, Maertens J, Schouten HC, Braakman E, Steijaart MMC, Zijlmans MJM, Slaper-Cortenbach I, Boogaerts MA, Löwenberg B, Verdonck LF: A randomized multicenter comparison of CD34+-selected progenitor cells from blood vs bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol 2003;31:855-864.
77. 6 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000;26:489-496.
78. Sohn SK, Kim JG, Kim DH, Lee NY, Suh JS, Lee KB: Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant 2003;31:967-972.
79. Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordigoni P, Cahn JY, Sadoun A, Ifrah N, Guyotat D, Faucher C, Fegueux N, Reiffers J, Maraninchi D, Blaise D: Higher doses of CD34+ perpheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003;17:869-875.
80. Morariu-Zamfir R, Rocha V, Devergie A, Socié, Ribaud P, Esperou H, Parquet N, Guardiola P, Dal Cortivo L, Bittencourt H, Garnier F, Traineau R, Marolleau JP, Chevret S, Gluckman E: Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia. Bone Marrow Transplant 2001;27:575-580.
81. Nakamura R, Bahceci E, Read EJ, Leitman SF, Cartner CS, Childs R, Dunbar CE, Gress R, Altemus R, Young NS, Barrett AJ: Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte addback. Br J Haematol 2001;115:95-104.
82. Urbano-Ispizua A, Carreras E, Marín, Rovira M, Martínez C, Fernández F, Xicoy B, Hernández JC, Montserrat E: Allogeneic transplantation of CD34+ selected cells from peripheral blood from human leukocyte antigen-identical siblings: Detrimental effect of a high number of donor CD34+ cells? Blood 2001;98:2352-2357.
83. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, De la Rubia J, Brunet S, Pérez-Oteyza J, Ferrá C, Zuazu J, Caballero D, Bargay J, Carvalhais A, Díez, Espigado I, Alegre A, Rovira M, Camphilo F, Odriozola J, Sanz MA, Sierra J, García-Conde J, Montserrat E: Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 2002;100:724-727.
84. Bahçeci E, Read EJ, Leitman S, Childs R, Dunbar C, Young NS, Barrett AJ: CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol 2000;108:408-414.
85. Noga SJ, Vogelsang GB, Miller SC, Meusel S, Loper K, Case R, Myers B, Rogers L, Flinn I, Borowitz M, O'Donnell P: Using point-of-care CD34 enumerations to optimize PBSC collection conditions. Cytotherapy 2001;3:11-18.
86. Trickett AE, Smith S, Kwan YL: Accurate calculation of blood volume to be processed by apheresis to achieve target CD34+ cell numbers for PBSC transplantation. Cytotherapy 2001;3:5-10.
87. Confer DL: Unrelated marrow donor registries. Curr Opin Hematol 1997;4:408-412.
88. Wagner JE, Barker JN, DeFor TE, Baker S, Blazar BR, Eide C, Goldman A, Kersey J, Krivit W, MacMillan ML, Orchard PJ, Peters C, Weisdorf DJ, Ramsay NKC, Davies SM: Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and non-malignant disease: Influences of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-1618.
89. Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E: Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000;342:1846-1854.
90. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, Gerson SL, Lazarus HM, Cairo M, Stevens CE, Rubinstein P, Kurtzberg J: Hematopoietic engraftment and survival in adult recipients of umbilical cord blood from unrelated donors. N Engl J Med 2001;344:1815-1822.
91. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, Ortega J, Souillet G, Ferreira E, Laporte JP, Fernandez M, Chastang C: Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997;337:373-381.
92. Lim FTH, Van Beckhoven JM, Brand A, Kluin-Nelemans JC, Hermans JMH, Willemze R, Kanhai HHH, Falkenburg JHF: The number of nucleated cells reflects the hematopoietic content of umbilical cord blood for transplantation. Bone Marrow Transplant;24:965-970.
93. Yang H, Acker JP, Hannon J, Miszta-Lane H, Akabutu JJ, McGann LE: Damage and protection of UC blood cells during cryopreservation. Cytotherapy 2001;3:377-386.
94. Migliaccio AR, Adamson JW, Stevens CE, Dobrila L, Carrier CM, Rubinstein P: Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: Graft progenitor cell content is a better predictor than nucleated cell quantity. Blood 2000;96:2717-2722.
95. Lowdell MW, Bainbidge DR: External quality assurance for CD34 - enumeration results of a preliminary national trial. Bone Marrow Transplant 1996;17:849-853.
96. Gratama JW, Kraan J, Levering W, Van Bockstaele DR, Rijkers G, Van der Schoot CE: Analysis of variation in results of CD34+ hematopoietic progenitor cell enumeration in a multicenter study. Cytometry 1997;30:109-117.
97. Beveridge R, Geller RB, Giguere J, Harden EA, Jansen J, Johnson DB, Menashe JI, Rifkin RM, Sayre RL, Shogan JE, Strnad CM: CD34 enumeration in a multicenter study. J Hematother 1997;6:285-286.
98. Chin-Yee I, Anderson L, Keeney M, Sutherland DR. Quality assurance of stem cell enumeration by flow cytometry. Cytometry 1997;30:296-303.
99. Serke S, Huhn D: Circulating CD34-expressing cells: German proficiency testing survey. J Hematother 1998;7:37-43.
100. Barnett D, Granger V, Storie I, Peel J, Pollitt R, Smart T, Reilly JT: Quality assessment of CD34+ stem cell enumeration: Experience of the United Kingdom National External Quality Assessment Scheme (UK-NEQAS) using a unique stable whole blood preparation. Br J Haematol 1998;102:553-565.
101. Dzik W, Sniecinski I, Fischer J: Toward standardization of CD34+ cell enumeration: An international study. Transfusion 1999;39:856-863.
102. Gratama JW, Kraan J, Keeney M, Sutherland DR, Granger V, Barnett D: Validation of the single-platform ISHAGE method for CD34+ hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy 2003;5:55-65.
103. pos cells. J Biol Regul Homeost Agents 2003;17:247-153.